SGLT2 inhibition and adipose tissue metabolism: current outlook and perspectives | Cardiovascular Diabetology
Zinman B, et al. Cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–28. https://doi.org/10.1056/NEJMoa1504720. Empagliflozin. Article CAS PubMed Google Scholar Mahaffey KW, et al. Canagliflozin for primary and Secondary Prevention of Cardiovascular Events: results from the CANVAS Program (Canagliflozin Cardiovascular Assessment Study). Circulation. 2018;137:323–34. https://doi.org/10.1161/CIRCULATIONAHA.117.032038. Article CAS PubMed PubMed Central Google … Read more